SG11201609350XA - Methods for inhibiting necroptosis - Google Patents

Methods for inhibiting necroptosis

Info

Publication number
SG11201609350XA
SG11201609350XA SG11201609350XA SG11201609350XA SG11201609350XA SG 11201609350X A SG11201609350X A SG 11201609350XA SG 11201609350X A SG11201609350X A SG 11201609350XA SG 11201609350X A SG11201609350X A SG 11201609350XA SG 11201609350X A SG11201609350X A SG 11201609350XA
Authority
SG
Singapore
Prior art keywords
methods
inhibiting necroptosis
necroptosis
inhibiting
Prior art date
Application number
SG11201609350XA
Inventor
Guillaume Laurent Lessene
Andrew Frederick Wilks
James Michael Murphy
Jean-Marc Garnier
Peter Edward Czabotar
Joanne Maree Hildebrand
Isabelle Lucet
John Hendry Silke
John Thomas Feutrill
Anthony Nicholas Cuzzupe
Pooja Sharma
Original Assignee
Catalyst Therapeutics Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2014901804A external-priority patent/AU2014901804A0/en
Application filed by Catalyst Therapeutics Pty Ltd filed Critical Catalyst Therapeutics Pty Ltd
Publication of SG11201609350XA publication Critical patent/SG11201609350XA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48Two nitrogen atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/04Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/02Antidotes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
SG11201609350XA 2014-05-15 2015-05-15 Methods for inhibiting necroptosis SG11201609350XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2014901804A AU2014901804A0 (en) 2014-05-15 Methods for inhibiting necroptosis
AU2014903569A AU2014903569A0 (en) 2014-09-08 Methods for inhibiting necroptosis
PCT/AU2015/050246 WO2015172203A1 (en) 2014-05-15 2015-05-15 Methods for inhibiting necroptosis

Publications (1)

Publication Number Publication Date
SG11201609350XA true SG11201609350XA (en) 2016-12-29

Family

ID=54479055

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201609350XA SG11201609350XA (en) 2014-05-15 2015-05-15 Methods for inhibiting necroptosis

Country Status (10)

Country Link
US (1) US20170114025A1 (en)
EP (1) EP3142667A4 (en)
JP (1) JP2017521477A (en)
CN (1) CN106456632A (en)
AU (1) AU2015258781A1 (en)
BR (1) BR112016026544A2 (en)
CA (1) CA2948544A1 (en)
RU (1) RU2016144911A (en)
SG (1) SG11201609350XA (en)
WO (1) WO2015172203A1 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110573509B (en) * 2017-02-28 2023-05-26 北京生命科学研究所 MLKL inhibitors
CN110769853B (en) * 2017-04-17 2022-06-03 北京生命科学研究所 Treatment of male aging
WO2019246163A1 (en) * 2018-06-18 2019-12-26 President And Fellows Of Harvard College Methods of inducing regulated cell death by administering mlkl modulators
AR115966A1 (en) 2018-08-17 2021-03-17 Pi Industries Ltd PHENYLAMIDINE COMPOUNDS AND THEIR USES
WO2021031893A1 (en) * 2019-08-21 2021-02-25 National Institute Of Biological Sciences, Beijing Prostatitis treatment
WO2021168521A1 (en) * 2020-02-27 2021-09-02 Anaxis Pharma Pty Ltd Inhibitors of necroptosis
EP3906924A1 (en) * 2020-05-08 2021-11-10 Eberhard Karls Universität Tübingen Modulation of mixed lineage kinase domain-like protein signaling
BR112022025732A2 (en) * 2020-06-19 2023-03-07 Anaxis Pharma Pty Ltd SULPHONAMIDE COMPOUNDS
WO2022065962A1 (en) * 2020-09-28 2022-03-31 한국화학연구원 Mlkl binding or degrading compound and pharmaceutical use thereof
WO2023115149A1 (en) * 2021-12-22 2023-06-29 Anaxis Pharma Pty Ltd Bifunctional sulphonamide compounds
CN117250353B (en) * 2023-11-16 2024-01-16 细胞生态海河实验室 Application of means for regulating and controlling programmed necrosis in preparing kit for diagnosing or delaying aging of blood system

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7459455B2 (en) * 2002-02-08 2008-12-02 Smithkline Beecham Corporation Pyrimidine compounds
US20110098288A1 (en) * 2008-03-11 2011-04-28 Jeremy Major Sulfonamides as zap-70 inhibitors
EP2475648A1 (en) * 2009-09-11 2012-07-18 Cellzome Limited Ortho substituted pyrimidine compounds as jak inhibitors

Also Published As

Publication number Publication date
US20170114025A1 (en) 2017-04-27
CN106456632A (en) 2017-02-22
BR112016026544A2 (en) 2017-12-12
WO2015172203A1 (en) 2015-11-19
RU2016144911A (en) 2018-06-18
EP3142667A4 (en) 2017-12-20
EP3142667A1 (en) 2017-03-22
AU2015258781A1 (en) 2016-11-24
JP2017521477A (en) 2017-08-03
CA2948544A1 (en) 2015-11-19

Similar Documents

Publication Publication Date Title
IL287113A (en) Smyd inhibitors
IL246785A0 (en) Benzimidazol-2-amines as midh1 inhibitors
GB201406151D0 (en) Method
GB201409558D0 (en) Method
GB201406155D0 (en) Method
HK1226398A1 (en) Benzimidazol-2-amines as midh1 inhibitors
GB201408119D0 (en) Method
IL248895A0 (en) Phosphatidylinositol -kinase inhibitors
GB201413086D0 (en) Methods
SG11201609350XA (en) Methods for inhibiting necroptosis
GB201403470D0 (en) Method
GB201410022D0 (en) Method
GB201420832D0 (en) Location method
GB201410101D0 (en) Method
GB201408745D0 (en) Methods
GB201409128D0 (en) Method
GB201409234D0 (en) Method
GB201409101D0 (en) Method
GB201415685D0 (en) Methods
GB201408649D0 (en) Method
GB201418154D0 (en) Inhibitors
AU2014903569A0 (en) Methods for inhibiting necroptosis
GB201414122D0 (en) Methods
AU2014901804A0 (en) Methods for inhibiting necroptosis
GB201410462D0 (en) Method